Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors

Porosnicu, Mercedes; Quinson, Anne-Marie; Crossley, Kate; Luecke, Stephan; Lauer, Ulrich M.

dc.contributor.author	Lauer, Ulrich Manfred
dc.date.accessioned	2023-01-09T08:47:22Z
dc.date.available	2023-01-09T08:47:22Z
dc.date.issued	2022
dc.identifier.issn	1479-6694
dc.identifier.uri	http://hdl.handle.net/10900/135018
dc.language.iso	en	de_DE
dc.publisher	Future Medicine Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.2217/fon-2022-0439	de_DE
dc.subject.ddc	610	de_DE
dc.title	Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors	de_DE
dc.type	Article	de_DE
utue.quellen.id	20220728000000_00380
utue.publikation.seiten	2627-2638	de_DE
utue.personen.roh	Porosnicu, Mercedes
utue.personen.roh	Quinson, Anne-Marie
utue.personen.roh	Crossley, Kate
utue.personen.roh	Luecke, Stephan
utue.personen.roh	Lauer, Ulrich M.
dcterms.isPartOf.ZSTitelID	Future Oncology	de_DE
dcterms.isPartOf.ZS-Issue	24	de_DE
dcterms.isPartOf.ZS-Volume	18	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE